222 related articles for article (PubMed ID: 22155544)
1. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Sheihet L; Garbuzenko OB; Bushman J; Gounder MK; Minko T; Kohn J
Eur J Pharm Sci; 2012 Feb; 45(3):320-9. PubMed ID: 22155544
[TBL] [Abstract][Full Text] [Related]
2. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
3. Functionalized nanospheres for targeted delivery of paclitaxel.
Bushman J; Vaughan A; Sheihet L; Zhang Z; Costache M; Kohn J
J Control Release; 2013 Nov; 171(3):315-21. PubMed ID: 23792807
[TBL] [Abstract][Full Text] [Related]
4. Encapsulating paclitaxel in polymeric nanomicelles increases antitumor activity and prevents peripheral neuropathy.
Oda CMR; Silva JO; Fernandes RS; Braga AV; Machado RR; Coelho MM; Cassali GD; Reis DC; de Barros ALB; Leite EA
Biomed Pharmacother; 2020 Dec; 132():110864. PubMed ID: 33254426
[TBL] [Abstract][Full Text] [Related]
5. In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
Chowdhury MR; Moshikur RM; Wakabayashi R; Tahara Y; Kamiya N; Moniruzzaman M; Goto M
Int J Pharm; 2019 Jun; 565():219-226. PubMed ID: 31077761
[TBL] [Abstract][Full Text] [Related]
6. A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety.
Wang Y; Wu KC; Zhao BX; Zhao X; Wang X; Chen S; Nie SF; Pan WS; Zhang X; Zhang Q
J Biomed Biotechnol; 2011; 2011():854872. PubMed ID: 21331356
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
8. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Ye J; Liu Y; Xia X; Meng L; Dong W; Wang R; Fu Z; Liu H; Han R
Oncol Rep; 2016 Jul; 36(1):399-409. PubMed ID: 27175803
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.
Zhang R; Luo K; Yang J; Sima M; Sun Y; Janát-Amsbury MM; Kopeček J
J Control Release; 2013 Feb; 166(1):66-74. PubMed ID: 23262201
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation.
Jain SK; Utreja P; Tiwary AK; Mahajan M; Kumar N; Roy P
Curr Drug Saf; 2014; 9(2):145-55. PubMed ID: 24369111
[TBL] [Abstract][Full Text] [Related]
11. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms.
Campos FC; Victorino VJ; Martins-Pinge MC; Cecchini AL; Panis C; Cecchini R
Food Chem Toxicol; 2014 Jun; 68():78-86. PubMed ID: 24657178
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
13. Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
El Nemr S; Al-Najjar BY; Omer HK; Elhissi AMA; Alhnan MA
Pharm Dev Technol; 2018 Jan; 23(1):67-75. PubMed ID: 28696155
[TBL] [Abstract][Full Text] [Related]
14. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicological studies of cremophor EL free alternative paclitaxel formulation.
Utreja P; Jain S; Yadav S; Khandhuja KL; Tiwary AK
Curr Drug Saf; 2011 Nov; 6(5):329-38. PubMed ID: 22424541
[TBL] [Abstract][Full Text] [Related]
16. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.
Tamura K; Kikuchi E; Konno T; Ishihara K; Matsumoto K; Miyajima A; Oya M
BMC Cancer; 2015 Apr; 15():317. PubMed ID: 25928041
[TBL] [Abstract][Full Text] [Related]
18. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
19. A micelle-shedding thermosensitive hydrogel as sustained release formulation.
de Graaf AJ; Azevedo Próspero dos Santos II; Pieters EH; Rijkers DT; van Nostrum CF; Vermonden T; Kok RJ; Hennink WE; Mastrobattista E
J Control Release; 2012 Sep; 162(3):582-90. PubMed ID: 22971272
[TBL] [Abstract][Full Text] [Related]
20. Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol.
Huang ST; Wang YP; Chen YH; Lin CT; Li WS; Wu HC
Int J Oncol; 2018 Sep; 53(3):1105-1117. PubMed ID: 29956746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
